CVCapsoVision Inc. Common Stock

Revenue up 10% with AI Highlights commercial launch in EU, but margin compression and FDA delays temper outlook.

CapsoVision (NASDAQ:CV) reported second-quarter revenue growth as sales of its CapsoCam Plus capsule endoscopy system increased, while the company advanced its artificial intelligence software rollout and development programs for colon and upper gastrointestinal applications. Revenue for the second

CapsoVision (NASDAQ:CV) reported steady first-quarter revenue and said it continues to advance artificial intelligence and capsule endoscopy programs aimed at expanding the use of its gastrointestinal imaging platform. On the company’s first-quarter 2026 earnings call, President and Chief Executive

The United States market has been flat over the last week but is up 30% over the past year, with earnings forecast to grow by 16% annually. In this environment, growth companies with significant insider ownership can be appealing as they often demonstrate strong commitment from those who know the business best.

CapsoVision (NASDAQ:CV) executives highlighted continued commercial growth for its CapsoCam Plus small-bowel capsule endoscopy product and provided updates on regulatory and clinical milestones for the company’s pipeline during its fourth-quarter and full-year 2025 earnings call. Commercial momentu

CapsoVision (NASDAQ:CV) executives used a fireside chat hosted by Roth Senior Research Analyst Kyle Bauser to outline the company’s origins, its capsule endoscopy platform for small bowel visualization, and development plans for future GI indications including colon and pancreas. Management also dis

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

As U.S. markets navigate a landscape of rising Treasury yields and uncertainty surrounding Federal Reserve policies, investors are keenly observing insider activities as a potential indicator of confidence in company growth prospects. In this climate, stocks with high insider ownership may signal strong alignment between management and shareholders, which can be particularly appealing when market conditions are volatile.

CV seeks FDA clearance to add AI-based reading to CapsoCam Plus to boost diagnostic accuracy and streamline reviews.

As the U.S. stock market experiences fluctuations, with the Dow Jones reaching new highs before pulling back and tech stocks facing pressure due to AI bubble concerns, investors are keenly observing insider activity as a potential indicator of confidence in growth companies. In this context, high insider ownership can be seen as a vote of confidence from those closest to the business, suggesting that these insiders believe in their company's long-term prospects despite current market volatility.